Download PDF Terns Pharmaceuticals Completes $80 Million Series B Financing to Advance Pipeline of Drugs to Treat NASH and Cancer Proceeds to Support Development of Clinical and Preclinical NASH Candidates Financing Led by Vivo Capital and OrbiMed, joined by Decheng Capital Lilly Asia Ventures, the Series A investor, also investing in the Series B round […]
Download PDF SAN MATEO, CA, and Shanghai, China, April 12, 2018 – Terns Pharmaceuticals Inc., a global biopharmaceutical company focused on discovering and developing molecularly-targeted, oral, small molecule drugs to treat liver disease and cancer, announced today the addition of Juan Carlos Lopez-Talavera, M.D., Ph.D. and Chuan (Joe) Shih, Ph.D. as scientific advisors. “As we […]
Download PDF Deal Includes an FXR Agonist, an SSAO Inhibitor and An Additional Candidate Against a Well-Validated NASH Target Development of Clinical Programs Will Focus on Regulatory Approval in China and Additional Global Markets SAN MATEO, Calif. ‐ Terns Pharmaceuticals Inc., a global biopharmaceutical company focused on discovering and developing molecularly targeted, oral, small molecule drugs […]
Terns is interested in partnering with life science and biopharmaceutical companies to rapidly advance its growing pipeline of compounds targeting liver diseases, cancer and infectious diseases, and bring those drugs to patients globally.
If you are interested in investing in Terns, or learning more about our business development efforts, please contact us.
Investors and Partners